Steven Gallinger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Steven Gallinger has a total of 166 co-authors. Here are the top co-authors by number of shared publications:
- Julie M. Wilson
PanCuRx Translational Research Initiative, Ontario institute for Cancer Research, Toronto, ON, Canada
7 shared publications - Grainne Mary O'KAne
Princess Margaret Cancer Centre, St Vincent's University Hospital and School of Medicine University College, Dublin, Ireland
6 shared publications - Jennifer J. Knox
Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, Canada
6 shared publications - Stephanie Ramotar
Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada
5 shared publications Anna Dodd
Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada
4 shared publications- Faiyaz Notta
Ontario Institute for Cancer Research, Toronto, Canada
4 shared publications
Latest Publications
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (11)
Impact of Clonal Hematopoiesis on Outcomes in Metastatic Pancreatic Ductal Adenocarcinoma: Analysis From the PASS-01 Trial
Purpose: Clonal hematopoiesis (CH) is increasingly recognized as a proinflammatory driver of adverse outcomes in solid tumors. Tumor-infiltrating immune cells with CH (TI-CH) actively promote tumor growth and those harboring TI-CH experience significantly worse survival. We investigated the prevalence and impact of CH on outcomes in patients with treatment-naïve metastatic pancreatic ductal adenocarcinoma (PDAC). Methods: Peripheral blood from 125 patients with metastatic PDAC enrolled in the PASS-01 trial (ClinicalTrials.gov identifier: NCT04469556 ) was evaluated. CH was defined as the presence of pathogenic or likely pathogenic variants with a variant allele frequency (VAF) of ≥1% in a 23 gene panel. Survival was estimated using the Kaplan-Meier method and compared using the log-rank test. Hazard ratios (HRs) were estimated using multivariable Cox proportional hazards regression. Results: CH was detected in 36.8% (46 of 125) of patients, and DNMT3A (60.9%) and TET2 (17.4%) were the most frequently mutated genes. There was no significant difference in progression-free survival (PFS; median, 4.9 v 5.2 months; HR, 1.01 [95% CI, 0.68 to 1.49]; P = .95) and overall survival (OS; median, 9.4 v 9.6 months; HR, 0.99 [95% CI, 0.63 to 1.53]; P = .95) between CH-positive and CH-negative patients, respectively. Among patients with basal-like subtype (n = 23), the presence of CH was associated with a numerically shorter PFS (median, 2.4 v 4.7 months; HR, 2.50 [95% CI, 0.93 to 6.84]; P = .06) and OS (median, 6.2 v 10.2 months; HR, 1.37 [95% CI, 0.51 to 3.69]; P = .52). In contrast, classical subtype showed no significant differences in survival outcomes by CH. Conclusion: CH is prevalent in metastatic PDAC but not independently prognostic. Further examination of CH in basal subtype tumors and the role of TI-CH in PDAC is needed.
- 1 November 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (11)
Impact of Clonal Hematopoiesis on Outcomes in Metastatic Pancreatic Ductal Adenocarcinoma: Analysis From the PASS-01 Trial
Purpose: Clonal hematopoiesis (CH) is increasingly recognized as a proinflammatory driver of adverse outcomes in solid tumors. Tumor-infiltrating immune cells with CH (TI-CH) actively promote tumor growth and those harboring TI-CH experience significantly worse survival. We investigated the prevalence and impact of CH on outcomes in patients with treatment-naïve metastatic pancreatic ductal adenocarcinoma (PDAC). Methods: Peripheral blood from 125 patients with metastatic PDAC enrolled in the PASS-01 trial (ClinicalTrials.gov identifier: NCT04469556 ) was evaluated. CH was defined as the presence of pathogenic or likely pathogenic variants with a variant allele frequency (VAF) of ≥1% in a 23 gene panel. Survival was estimated using the Kaplan-Meier method and compared using the log-rank test. Hazard ratios (HRs) were estimated using multivariable Cox proportional hazards regression. Results: CH was detected in 36.8% (46 of 125) of patients, and DNMT3A (60.9%) and TET2 (17.4%) were the most frequently mutated genes. There was no significant difference in progression-free survival (PFS; median, 4.9 v 5.2 months; HR, 1.01 [95% CI, 0.68 to 1.49]; P = .95) and overall survival (OS; median, 9.4 v 9.6 months; HR, 0.99 [95% CI, 0.63 to 1.53]; P = .95) between CH-positive and CH-negative patients, respectively. Among patients with basal-like subtype (n = 23), the presence of CH was associated with a numerically shorter PFS (median, 2.4 v 4.7 months; HR, 2.50 [95% CI, 0.93 to 6.84]; P = .06) and OS (median, 6.2 v 10.2 months; HR, 1.37 [95% CI, 0.51 to 3.69]; P = .52). In contrast, classical subtype showed no significant differences in survival outcomes by CH. Conclusion: CH is prevalent in metastatic PDAC but not independently prognostic. Further examination of CH in basal subtype tumors and the role of TI-CH in PDAC is needed.
- Open Access
Transcriptomic, Genomic, and Clinical Characterization of Morphological Classes in Localized and Metastatic Pancreatic Cancer
Background: Histomorphology is a strong prognostic biomarker correlated with basal-like and classical programs in surgically resected pancreatic ductal adenocarcinoma (PDAC). However, the spectrum of morphology and its biological associations remain poorly defined in advanced disease. Objectives: We explored the transcriptomic and genomic underpinnings and clinical relevance of morphological classes across localized and metastatic PDAC. Design: We unified morphological classifications into four classes: glandular, cribriform, solid, and squamous. We integrated transcriptome and whole–genome sequencing following laser–capture microdissection with morphological classifications in 348 PDAC patients, where half of the cohort included locally advance and metastatic stages to uncover molecular associations. Results: Non–glandular morphologies comprised three distinct classes that were enriched in metastatic disease. Transcriptomic profiling exhibited that glandular tumours predominantly expressed classical epithelial programs, although a subset displayed partial or full epithelial–mesenchymal transition signatures. In contrast, non–glandular morphologies showed basal–like transcriptional programs with subtype–specific pathways, including ciliogenesis in cribriform tumours, extracellular matrix remodelling and immune evasion in solid tumours, and keratinisation programs in squamous tumours. The solid class was significantly enriched in liver metastatic lesions and was associated with increased intra– tumoural morphological heterogeneity, whole-genome doubling, KRAS major allelic imbalance, and elevated KRAS–ERK signalling. Conclusion: Non–glandular morphologies identify biologically distinct PDAC tumor states that are enriched in liver metastases and associated with subtype–specific transcriptional programs and KRAS–driven genomic alterations.
Open AccessTranscriptomic, Genomic, and Clinical Characterization of Morphological Classes in Localized and Metastatic Pancreatic Cancer
Background: Histomorphology is a strong prognostic biomarker correlated with basal-like and classical programs in surgically resected pancreatic ductal adenocarcinoma (PDAC). However, the spectrum of morphology and its biological associations remain poorly defined in advanced disease. Objectives: We explored the transcriptomic and genomic underpinnings and clinical relevance of morphological classes across localized and metastatic PDAC. Design: We unified morphological classifications into four classes: glandular, cribriform, solid, and squamous. We integrated transcriptome and whole–genome sequencing following laser–capture microdissection with morphological classifications in 348 PDAC patients, where half of the cohort included locally advance and metastatic stages to uncover molecular associations. Results: Non–glandular morphologies comprised three distinct classes that were enriched in metastatic disease. Transcriptomic profiling exhibited that glandular tumours predominantly expressed classical epithelial programs, although a subset displayed partial or full epithelial–mesenchymal transition signatures. In contrast, non–glandular morphologies showed basal–like transcriptional programs with subtype–specific pathways, including ciliogenesis in cribriform tumours, extracellular matrix remodelling and immune evasion in solid tumours, and keratinisation programs in squamous tumours. The solid class was significantly enriched in liver metastatic lesions and was associated with increased intra– tumoural morphological heterogeneity, whole-genome doubling, KRAS major allelic imbalance, and elevated KRAS–ERK signalling. Conclusion: Non–glandular morphologies identify biologically distinct PDAC tumor states that are enriched in liver metastases and associated with subtype–specific transcriptional programs and KRAS–driven genomic alterations.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (2) , e2500268
Deep Learning of Histopathology Predicts Outcomes After Surgery for Pancreatic Cancer
PURPOSE: Predicting recurrence of pancreatic cancer after surgery could inform clinical decision making, including adjuvant therapies and follow-up. This study aimed to develop and validate a deep learning model using digitized whole-slide images (WSI) of histopathology. METHODS: Publicly available WSI of pancreatic ductal adenocarcinoma resections from three cohorts were used for training. The model consisted of a pan-cancer foundation model to generate embeddings, mean-pooling across tissue patches, and then a fully connected neural network. Model predictions were compared with human-labeled histopathologic features and genomic alterations. The model was externally validated in a meta-analysis of a single-center cohort from Princess Margaret Cancer Centre, a multicenter cohort from France, and the PRODIGE 24 trial of adjuvant chemotherapy. RESULTS: The deep learning model was trained on 12,594 tissue patches from 257 patients. High-risk classifications were associated with squamous morphology, reactive stroma, tumor cellularity, and necrosis, whereas low-risk classifications were associated with tubulopapillary and conventional morphologies, as well as deserted stroma. High-risk cancers were enriched for basal-like gene expression profiles and distinct oncogenic pathways. In a meta-analysis of the external cohorts, the hazard ratio (HR) for death comparing high-versus low-risk cancers was 1.49 (95% CI, 1.25 to 1.79, P < .001), whereas the HR for recurrence or death was 1.41 (95% CI, 1.19 to 1.68, P < .001). The classifications remained prognostic among moderately differentiated cancers. CONCLUSION: An open-source deep learning model using WSI from pancreatic cancer resections generated risk classifications that correlated with histopathologic and genomic features. Classifications were externally validated in a meta-analysis of three cohorts. This model could be applied to WSI to provide individualized prognostic information for patients.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (2) , e2500268
Deep Learning of Histopathology Predicts Outcomes After Surgery for Pancreatic Cancer
PURPOSE: Predicting recurrence of pancreatic cancer after surgery could inform clinical decision making, including adjuvant therapies and follow-up. This study aimed to develop and validate a deep learning model using digitized whole-slide images (WSI) of histopathology. METHODS: Publicly available WSI of pancreatic ductal adenocarcinoma resections from three cohorts were used for training. The model consisted of a pan-cancer foundation model to generate embeddings, mean-pooling across tissue patches, and then a fully connected neural network. Model predictions were compared with human-labeled histopathologic features and genomic alterations. The model was externally validated in a meta-analysis of a single-center cohort from Princess Margaret Cancer Centre, a multicenter cohort from France, and the PRODIGE 24 trial of adjuvant chemotherapy. RESULTS: The deep learning model was trained on 12,594 tissue patches from 257 patients. High-risk classifications were associated with squamous morphology, reactive stroma, tumor cellularity, and necrosis, whereas low-risk classifications were associated with tubulopapillary and conventional morphologies, as well as deserted stroma. High-risk cancers were enriched for basal-like gene expression profiles and distinct oncogenic pathways. In a meta-analysis of the external cohorts, the hazard ratio (HR) for death comparing high-versus low-risk cancers was 1.49 (95% CI, 1.25 to 1.79, P < .001), whereas the HR for recurrence or death was 1.41 (95% CI, 1.19 to 1.68, P < .001). The classifications remained prognostic among moderately differentiated cancers. CONCLUSION: An open-source deep learning model using WSI from pancreatic cancer resections generated risk classifications that correlated with histopathologic and genomic features. Classifications were externally validated in a meta-analysis of three cohorts. This model could be applied to WSI to provide individualized prognostic information for patients.
- Top Cited Papers
- 1 November 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (31) , 3355-3368
PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer
PURPOSE: To assess modified folinic acid/leucovorin, fluorouracil, irinotecan, oxaliplatin (FOLFIRINOX [mFFX]) versus gemcitabine/nab-paclitaxel (GnP) in de novo metastatic pancreatic ductal adenocarcinoma (PDAC) and explore predictive biomarkers. PATIENTS AND METHODS: Patients were randomly assigned 1:1 to mFFX or GnP with exclusion of germline pathogenic variants in BRCA1/2 or PALB2 . The primary end point was progression-free survival (PFS) between arms with 0.3 significance. The per-protocol (PP) population included patients who received one dose of chemotherapy. Pretreatment biopsies underwent whole-genome/transcriptome sequencing and patient-derived organoid (PDO) development, providing correlate recommendations at a molecular tumor board and outcomes assessed according to RNA signatures (basal-like v classical). RESULTS: Of 160 patients randomly assigned (80 mFFX, 80 GnP), 140 patients were in the PP population (71 mFFX, 69 GnP), with median follow-up of 8.3 months. The median PFS was 4.0 months for mFFX versus 5.3 months for GnP (hazard ratio [HR], 1.37 [95% CI, 0.97 to 1.92]; P = .069) in intention-to-treat. Median overall survival (OS) was 8.5 months with mFFX and 9.7 months with GnP (HR, 1.57 [95% CI, 1.08 to 2.28]; P = .017). Genomic data were generated in 94%, transcriptomes in 74%, and PDOs in 50%. The median PFS for those with basal-like was 3.0 (mFFX) and 5.5 (GnP) months ( P = .17), and classical PDAC was 6.3 (mFFX) versus 5.4 (GnP) months ( P = .36). The median OS in basal-like was 7.5 (mFFX) and 8.9 (GnP) months ( P = .75) versus in classical OS was 9.7 (mFFX) and 13.9 (GnP) months ( P = .047). Overall, 75 (54%) of patients received second-line treatment, 33/75 (44%) correlate-guided. The median time on second-line treatment was only 2.1 months with a median OS of 5.4 months for a correlate-guided choice versus 4.4 months on a standard chemotherapy approach ( P = .45). CONCLUSION: In the phase II Pancreatic Adenocarcinoma Signature Stratification for Treatment-01 (PASS-01) trial population, PFS was similar between GnP and mFFX; however, OS and safety trends favored GnP. The second-line setting appears inadequate to offer precision choices, given the short survival observed.
- 1 November 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (31) , 3355-3368
Top Cited PapersPASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer
PURPOSE: To assess modified folinic acid/leucovorin, fluorouracil, irinotecan, oxaliplatin (FOLFIRINOX [mFFX]) versus gemcitabine/nab-paclitaxel (GnP) in de novo metastatic pancreatic ductal adenocarcinoma (PDAC) and explore predictive biomarkers. PATIENTS AND METHODS: Patients were randomly assigned 1:1 to mFFX or GnP with exclusion of germline pathogenic variants in BRCA1/2 or PALB2 . The primary end point was progression-free survival (PFS) between arms with 0.3 significance. The per-protocol (PP) population included patients who received one dose of chemotherapy. Pretreatment biopsies underwent whole-genome/transcriptome sequencing and patient-derived organoid (PDO) development, providing correlate recommendations at a molecular tumor board and outcomes assessed according to RNA signatures (basal-like v classical). RESULTS: Of 160 patients randomly assigned (80 mFFX, 80 GnP), 140 patients were in the PP population (71 mFFX, 69 GnP), with median follow-up of 8.3 months. The median PFS was 4.0 months for mFFX versus 5.3 months for GnP (hazard ratio [HR], 1.37 [95% CI, 0.97 to 1.92]; P = .069) in intention-to-treat. Median overall survival (OS) was 8.5 months with mFFX and 9.7 months with GnP (HR, 1.57 [95% CI, 1.08 to 2.28]; P = .017). Genomic data were generated in 94%, transcriptomes in 74%, and PDOs in 50%. The median PFS for those with basal-like was 3.0 (mFFX) and 5.5 (GnP) months ( P = .17), and classical PDAC was 6.3 (mFFX) versus 5.4 (GnP) months ( P = .36). The median OS in basal-like was 7.5 (mFFX) and 8.9 (GnP) months ( P = .75) versus in classical OS was 9.7 (mFFX) and 13.9 (GnP) months ( P = .047). Overall, 75 (54%) of patients received second-line treatment, 33/75 (44%) correlate-guided. The median time on second-line treatment was only 2.1 months with a median OS of 5.4 months for a correlate-guided choice versus 4.4 months on a standard chemotherapy approach ( P = .45). CONCLUSION: In the phase II Pancreatic Adenocarcinoma Signature Stratification for Treatment-01 (PASS-01) trial population, PFS was similar between GnP and mFFX; however, OS and safety trends favored GnP. The second-line setting appears inadequate to offer precision choices, given the short survival observed.
- Open Access
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 9 (9) , e2500073
Development of Machine Learning Systems to Predict Cancer-Related Symptoms With Validation Across a Health Care System
PURPOSE: Cancer and its treatment cause symptoms. In this study, we aimed to develop machine learning (ML) systems that predict future symptom deterioration among people receiving treatment for cancer and then validate the systems in a simulated deployment across an entire health care system. METHODS: We trained and tested ML systems that predict a deterioration in nine patient-reported symptoms within 30 days after treatments for aerodigestive cancers, using internal electronic health record (EHR) data at Princess Margaret Cancer Centre (3,229 patients; 20,267 treatments). The primary performance metric was the area under the receiver operating characteristic curve (AUROC). The best-performing systems in the held-out internal test set were then externally validated across 82 cancer centers in Ontario (12,079 patients; 77,003 treatments) by adapting techniques from meta-analysis. RESULTS: The best ML systems predicted symptom deterioration with AUROCs ranging from 0.66 (95% CI, 0.63 to 0.69) for dyspnea to 0.73 (95% CI, 0.71 to 0.75) for drowsiness in the internal test cohort. Treatments flagged as high-risk were significantly associated with future symptom deterioration (odds ratios [ORs], 2.53-6.56; all P < .001) and emergency department visits for dyspnea (OR, 1.85; P = .008), depression (OR, 1.84; P = .04), and anxiety (OR, 2.66; P < .001). In the external validation cohort, the AUROCs for different symptoms meta-analyzed across centers ranged from 0.67 (95% CI, 0.66 to 0.68) to 0.73 (95% CI, 0.72 to 0.74). Performance across centers displayed significant heterogeneity for six of nine symptoms (I 2 , 46.4%-66.9%; P = .004 for dyspnea, P < .001 for the rest). CONCLUSION: ML can predict future symptoms among people with cancer from routine EHR data, which could guide personalized interventions. Heterogeneous performance across centers must be considered when systems are deployed across a health care system.
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 9 (9) , e2500073
Open AccessDevelopment of Machine Learning Systems to Predict Cancer-Related Symptoms With Validation Across a Health Care System
PURPOSE: Cancer and its treatment cause symptoms. In this study, we aimed to develop machine learning (ML) systems that predict future symptom deterioration among people receiving treatment for cancer and then validate the systems in a simulated deployment across an entire health care system. METHODS: We trained and tested ML systems that predict a deterioration in nine patient-reported symptoms within 30 days after treatments for aerodigestive cancers, using internal electronic health record (EHR) data at Princess Margaret Cancer Centre (3,229 patients; 20,267 treatments). The primary performance metric was the area under the receiver operating characteristic curve (AUROC). The best-performing systems in the held-out internal test set were then externally validated across 82 cancer centers in Ontario (12,079 patients; 77,003 treatments) by adapting techniques from meta-analysis. RESULTS: The best ML systems predicted symptom deterioration with AUROCs ranging from 0.66 (95% CI, 0.63 to 0.69) for dyspnea to 0.73 (95% CI, 0.71 to 0.75) for drowsiness in the internal test cohort. Treatments flagged as high-risk were significantly associated with future symptom deterioration (odds ratios [ORs], 2.53-6.56; all P < .001) and emergency department visits for dyspnea (OR, 1.85; P = .008), depression (OR, 1.84; P = .04), and anxiety (OR, 2.66; P < .001). In the external validation cohort, the AUROCs for different symptoms meta-analyzed across centers ranged from 0.67 (95% CI, 0.66 to 0.68) to 0.73 (95% CI, 0.72 to 0.74). Performance across centers displayed significant heterogeneity for six of nine symptoms (I 2 , 46.4%-66.9%; P = .004 for dyspnea, P < .001 for the rest). CONCLUSION: ML can predict future symptoms among people with cancer from routine EHR data, which could guide personalized interventions. Heterogeneous performance across centers must be considered when systems are deployed across a health care system.
- Open Access
- 12 May 2023
- Published by Springer Nature in Diabetologia
- Vol. 66 (8) , 1481-1500
Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis
Aims/hypothesis: Epidemiological studies have generated conflicting findings on the relationship between glucose-lowering medication use and cancer risk. Naturally occurring variation in genes encoding glucose-lowering drug targets can be used to investigate the effect of their pharmacological perturbation on cancer risk. Methods: We developed genetic instruments for three glucose-lowering drug targets (peroxisome proliferator activated receptor γ [PPARG]; sulfonylurea receptor 1 [ATP binding cassette subfamily C member 8 (ABCC8)]; glucagon-like peptide 1 receptor [GLP1R]) using summary genetic association data from a genome-wide association study of type 2 diabetes in 148,726 cases and 965,732 controls in the Million Veteran Program. Genetic instruments were constructed using cis-acting genome-wide significant (p−8) SNPs permitted to be in weak linkage disequilibrium (r21c: OR 1.75 [95% CI 1.07, 2.85], p=0.02). In histological subtype-stratified analyses, genetically proxied PPARG perturbation was weakly associated with lower risk of oestrogen receptor-positive breast cancer (OR 0.57 [95% CI 0.38, 0.85], p=6.45×10−3). In co-localisation analysis, however, there was little evidence of shared causal variants for type 2 diabetes liability and cancer endpoints in the PPARG locus, although these analyses were likely underpowered. There was little evidence to support associations between genetically proxied PPARG perturbation and colorectal or overall cancer risk or between genetically proxied ABCC8 or GLP1R perturbation with risk across cancer endpoints. Conclusions/interpretation: Our drug target MR analyses did not find consistent evidence to support an association of genetically proxied PPARG, ABCC8 or GLP1R perturbation with breast, colorectal, prostate or overall cancer risk. Further evaluation of these drug targets using alternative molecular epidemiological approaches may help to further corroborate the findings presented in this analysis. Data availability: Summary genetic association data for select cancer endpoints were obtained from the public domain: breast cancer (https://bcac.ccge.medschl.cam.ac.uk/bcacdata/); and overall prostate cancer (http://practical.icr.ac.uk/blog/). Summary genetic association data for colorectal cancer can be accessed by contacting GECCO (kafdem at fredhutch.org). Summary genetic association data on advanced prostate cancer can be accessed by contacting PRACTICAL (practical at icr.ac.uk). Summary genetic association data on type 2 diabetes from Vujkovic et al (Nat Genet, 2020) can be accessed through dbGAP under accession number phs001672.v3.p1 (pha004945.1 refers to the European-specific summary statistics). UK Biobank data can be accessed by registering with UK Biobank and completing the registration form in the Access Management System (AMS) (https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access). Graphical
- 12 May 2023
- Published by Springer Nature in Diabetologia
- Vol. 66 (8) , 1481-1500
Open AccessGenetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis
Aims/hypothesis: Epidemiological studies have generated conflicting findings on the relationship between glucose-lowering medication use and cancer risk. Naturally occurring variation in genes encoding glucose-lowering drug targets can be used to investigate the effect of their pharmacological perturbation on cancer risk. Methods: We developed genetic instruments for three glucose-lowering drug targets (peroxisome proliferator activated receptor γ [PPARG]; sulfonylurea receptor 1 [ATP binding cassette subfamily C member 8 (ABCC8)]; glucagon-like peptide 1 receptor [GLP1R]) using summary genetic association data from a genome-wide association study of type 2 diabetes in 148,726 cases and 965,732 controls in the Million Veteran Program. Genetic instruments were constructed using cis-acting genome-wide significant (p−8) SNPs permitted to be in weak linkage disequilibrium (r21c: OR 1.75 [95% CI 1.07, 2.85], p=0.02). In histological subtype-stratified analyses, genetically proxied PPARG perturbation was weakly associated with lower risk of oestrogen receptor-positive breast cancer (OR 0.57 [95% CI 0.38, 0.85], p=6.45×10−3). In co-localisation analysis, however, there was little evidence of shared causal variants for type 2 diabetes liability and cancer endpoints in the PPARG locus, although these analyses were likely underpowered. There was little evidence to support associations between genetically proxied PPARG perturbation and colorectal or overall cancer risk or between genetically proxied ABCC8 or GLP1R perturbation with risk across cancer endpoints. Conclusions/interpretation: Our drug target MR analyses did not find consistent evidence to support an association of genetically proxied PPARG, ABCC8 or GLP1R perturbation with breast, colorectal, prostate or overall cancer risk. Further evaluation of these drug targets using alternative molecular epidemiological approaches may help to further corroborate the findings presented in this analysis. Data availability: Summary genetic association data for select cancer endpoints were obtained from the public domain: breast cancer (https://bcac.ccge.medschl.cam.ac.uk/bcacdata/); and overall prostate cancer (http://practical.icr.ac.uk/blog/). Summary genetic association data for colorectal cancer can be accessed by contacting GECCO (kafdem at fredhutch.org). Summary genetic association data on advanced prostate cancer can be accessed by contacting PRACTICAL (practical at icr.ac.uk). Summary genetic association data on type 2 diabetes from Vujkovic et al (Nat Genet, 2020) can be accessed through dbGAP under accession number phs001672.v3.p1 (pha004945.1 refers to the European-specific summary statistics). UK Biobank data can be accessed by registering with UK Biobank and completing the registration form in the Access Management System (AMS) (https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access). Graphical
- 27 February 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (6) , 3866-3867
ASO Visual Abstract: Optimizing Circulating Tumor DNA Use in the Perioperative Setting for Intrahepatic Cholangiocarcinoma—Diagnosis, Screening, Minimal Residual Disease Detection, and Treatment Response Monitoring
- 27 February 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (6) , 3866-3867
ASO Visual Abstract: Optimizing Circulating Tumor DNA Use in the Perioperative Setting for Intrahepatic Cholangiocarcinoma—Diagnosis, Screening, Minimal Residual Disease Detection, and Treatment Response Monitoring
- Open Access
- 20 February 2023
- Published by The Korean Association of Hepato-Biliary-Pancreatic Surgery in Annals of Hepato-Biliary-Pancreatic Surgery
- Vol. 27 (2) , 158-165
Preoperative neutrophil-to-lymphocyte ratio is prognostic for early recurrence after curative intrahepatic cholangiocarcinoma resection
Woo Jin Choi, Fiorella Murillo Perez, Annabel Gravely, Tommy Ivanics, Marco P. A. W. Claasen, Liza Abraham, Phillipe Abreu, Robin Visser, Steven Gallinger, Bettina E. Hansen, Gonzalo Sapisochin. Ann Hepatobiliary Pancreat Surg 2023;27:158-65. https://doi.org/10.14701/ahbps.22-114
- 20 February 2023
- Published by The Korean Association of Hepato-Biliary-Pancreatic Surgery in Annals of Hepato-Biliary-Pancreatic Surgery
- Vol. 27 (2) , 158-165
Open AccessPreoperative neutrophil-to-lymphocyte ratio is prognostic for early recurrence after curative intrahepatic cholangiocarcinoma resection
Woo Jin Choi, Fiorella Murillo Perez, Annabel Gravely, Tommy Ivanics, Marco P. A. W. Claasen, Liza Abraham, Phillipe Abreu, Robin Visser, Steven Gallinger, Bettina E. Hansen, Gonzalo Sapisochin. Ann Hepatobiliary Pancreat Surg 2023;27:158-65. https://doi.org/10.14701/ahbps.22-114
- Open Access
- 15 November 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (22_Supplem) , A003
Abstract A003: Developmental parallels in pancreatic cancer subtypes revealed by single cell transcriptomics
Recent research into the transcriptional subtypes in pancreatic ductal adenocarcinoma (PDA) has demonstrated their importance in predicting survival and therapeutic response. The Basal-like subtype is enriched in metastases and generally predicts poorer prognosis, while the Classical subtype is defined by gene expression reflective of pancreatic progenitors. The two-subtype scheme can be further subdivided into five subtypes that help better reflect the vast transcriptional heterogeneity found in PDA tumors. Basal-like A tumors fare worse than Basal-like B tumors. KRAS wildtype tumors are enriched in Classical B, which have the best prognosis, while Classical A is more reflective of the two-subtype Classical program. Hybrid tumors, generally a mix of Basal-like B and Classical A, are intermediate in prognosis between the Classical and Basal-like subtypes. Despite the importance of the subtypes, we have yet to fully understand how subtype programs within single cells of a tumor are intrinsically regulated, and how they contribute to tumor-level transcriptional observations. To investigate, we generated and leveraged a single cell RNA sequencing dataset enriched for malignant tumor cells spanning both primary and metastatic disease. Along with the richly annotated COMPASS dataset featuring bulk RNA sequencing of over 300 laser captured samples, we developed a single sample classifier utilizing gene pairs for assigning Basal-like A, Basal-like B, Hybrid, Classical A or Classical B to bulk tumors as well as individual cells, allowing interrogation of the subtypes across modalities. We find that the bulk subtype of the tumor is generally reflected in the dominant cell subtype. However, there are frequently cells of other subtypes within individual tumors, and substantial differences in cell subtype composition across tumors of the same subtype. In addition, we find that the proportion of Basal-like cells is a significant risk prognosticator. Investigating deeper into the transcriptional drivers of the subtypes reveals differences in expression of programs linked to endodermal development. Transcription factors such as FOXC1 and IRX3 generally related to foregut development are enriched in Basal-like A, forming a gradient of high expression to lower expression from Basal-like A, Basal-like B, Hybrid, Classical A to Classical B. Interestingly, midgut transcription factors such as CDX2 and ELF3 are expressed in the reverse order. Integrating data from single cell endoderm RNA sequencing further supports this finding, suggesting that the subtypes may arise from tumor cells exploiting pathways normally expressed early in development. This work provides a stepping stone to better understanding the mechanisms behind transcriptional subtypes in PDA. Citation Format: Sabrina Ge, Gun Ho Jang, Michelle Chan-Seng-Yue, Eugenia Flores Figueroa, Karen Ng, Stephanie Ramotar, Anna Dodd, Grainne M. O'Kane, Julie M. Wilson, Jennifer J. Knox, Sandra E. Fischer, Steven Gallinger, Faiyaz Notta. Developmental parallels in pancreatic cancer subtypes revealed by single cell transcriptomics [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr A003.
- 15 November 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (22_Supplem) , A003
Open AccessAbstract A003: Developmental parallels in pancreatic cancer subtypes revealed by single cell transcriptomics
Recent research into the transcriptional subtypes in pancreatic ductal adenocarcinoma (PDA) has demonstrated their importance in predicting survival and therapeutic response. The Basal-like subtype is enriched in metastases and generally predicts poorer prognosis, while the Classical subtype is defined by gene expression reflective of pancreatic progenitors. The two-subtype scheme can be further subdivided into five subtypes that help better reflect the vast transcriptional heterogeneity found in PDA tumors. Basal-like A tumors fare worse than Basal-like B tumors. KRAS wildtype tumors are enriched in Classical B, which have the best prognosis, while Classical A is more reflective of the two-subtype Classical program. Hybrid tumors, generally a mix of Basal-like B and Classical A, are intermediate in prognosis between the Classical and Basal-like subtypes. Despite the importance of the subtypes, we have yet to fully understand how subtype programs within single cells of a tumor are intrinsically regulated, and how they contribute to tumor-level transcriptional observations. To investigate, we generated and leveraged a single cell RNA sequencing dataset enriched for malignant tumor cells spanning both primary and metastatic disease. Along with the richly annotated COMPASS dataset featuring bulk RNA sequencing of over 300 laser captured samples, we developed a single sample classifier utilizing gene pairs for assigning Basal-like A, Basal-like B, Hybrid, Classical A or Classical B to bulk tumors as well as individual cells, allowing interrogation of the subtypes across modalities. We find that the bulk subtype of the tumor is generally reflected in the dominant cell subtype. However, there are frequently cells of other subtypes within individual tumors, and substantial differences in cell subtype composition across tumors of the same subtype. In addition, we find that the proportion of Basal-like cells is a significant risk prognosticator. Investigating deeper into the transcriptional drivers of the subtypes reveals differences in expression of programs linked to endodermal development. Transcription factors such as FOXC1 and IRX3 generally related to foregut development are enriched in Basal-like A, forming a gradient of high expression to lower expression from Basal-like A, Basal-like B, Hybrid, Classical A to Classical B. Interestingly, midgut transcription factors such as CDX2 and ELF3 are expressed in the reverse order. Integrating data from single cell endoderm RNA sequencing further supports this finding, suggesting that the subtypes may arise from tumor cells exploiting pathways normally expressed early in development. This work provides a stepping stone to better understanding the mechanisms behind transcriptional subtypes in PDA. Citation Format: Sabrina Ge, Gun Ho Jang, Michelle Chan-Seng-Yue, Eugenia Flores Figueroa, Karen Ng, Stephanie Ramotar, Anna Dodd, Grainne M. O'Kane, Julie M. Wilson, Jennifer J. Knox, Sandra E. Fischer, Steven Gallinger, Faiyaz Notta. Developmental parallels in pancreatic cancer subtypes revealed by single cell transcriptomics [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr A003.
- Open Access
- 15 November 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (22_Supplem) , B036
Abstract B036: The role of whole genome duplication in progression of pancreatic ductal adenocarcinoma
Introduction: Pancreatic ductal adenocarcinoma (PDA) is a lethal disease that tends to present at an advanced stage, but the evolutionary mechanisms responsible for rapid progression in PDA are poorly understood. Whole genome duplication (WGD) is a hallmark of cancer observed more frequently in late-stage tumors that predicts poorer overall patient survival across cancer types, including PDA. The genome-wide instability that occurs during WGD events can lead to gene dosage imbalances that promote tumor progression and may explain the rapid progression of aneuploidy. Although WGD has been studied extensively in advanced cancer, there is limited data on WGD in primary tumors. We hypothesize that WGD occurs frequently in primary PDA and promotes the rapid progression and high rate of relapse in early stage PDA. We leveraged scWGS to infer copy number profiles and WGD events from tumor cells to determine the rate of subclonal WGD in primary PDA tumors and understand how aneuploidy and genome instability evolve in the earliest stages of tumor progression. Methods: Single cell barcoded libraries from primary treatment naive tumors were prepared with the 10X Genomics Single Cell CNV platform and sequenced to a depth of 20-60x per tumor. Reads were processed using CellRanger DNA pipeline, demultiplexed, and analyzed with Gingko CNV. A total of 10,323 cells from 8 primary PDA tumors (range, 192 – 3146; median = 1286) were recovered, resulting in an average coverage of 0.06x per single cell (range, 0.02x – 0.14x). Results: 5/8 tumors analyzed had evidence of at least one WGD event. The WGD event was identified as a minor subclone in 3 of these 5. Copy number profiles revealed 1-6 distinct subclones in each tumor, demonstrating copy number evolution is ongoing. WGD+ tumors trend towards having higher diversity and higher percentage of genome altered. Conclusion: WGD occurs more frequently in primary PDA than previously understood, and may confer high levels of genetic instability. Citation Format: Lauren Hummel, Irene Xie, Karen Ng, Amy Zhang, Stephanie Ramotar, Anna Dodd, Grainne O'Kane, Jennifer Knox, Julie Wilson, Steven Gallinger, Faiyaz Notta. The role of whole genome duplication in progression of pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr B036.
- 15 November 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (22_Supplem) , B036
Open AccessAbstract B036: The role of whole genome duplication in progression of pancreatic ductal adenocarcinoma
Introduction: Pancreatic ductal adenocarcinoma (PDA) is a lethal disease that tends to present at an advanced stage, but the evolutionary mechanisms responsible for rapid progression in PDA are poorly understood. Whole genome duplication (WGD) is a hallmark of cancer observed more frequently in late-stage tumors that predicts poorer overall patient survival across cancer types, including PDA. The genome-wide instability that occurs during WGD events can lead to gene dosage imbalances that promote tumor progression and may explain the rapid progression of aneuploidy. Although WGD has been studied extensively in advanced cancer, there is limited data on WGD in primary tumors. We hypothesize that WGD occurs frequently in primary PDA and promotes the rapid progression and high rate of relapse in early stage PDA. We leveraged scWGS to infer copy number profiles and WGD events from tumor cells to determine the rate of subclonal WGD in primary PDA tumors and understand how aneuploidy and genome instability evolve in the earliest stages of tumor progression. Methods: Single cell barcoded libraries from primary treatment naive tumors were prepared with the 10X Genomics Single Cell CNV platform and sequenced to a depth of 20-60x per tumor. Reads were processed using CellRanger DNA pipeline, demultiplexed, and analyzed with Gingko CNV. A total of 10,323 cells from 8 primary PDA tumors (range, 192 – 3146; median = 1286) were recovered, resulting in an average coverage of 0.06x per single cell (range, 0.02x – 0.14x). Results: 5/8 tumors analyzed had evidence of at least one WGD event. The WGD event was identified as a minor subclone in 3 of these 5. Copy number profiles revealed 1-6 distinct subclones in each tumor, demonstrating copy number evolution is ongoing. WGD+ tumors trend towards having higher diversity and higher percentage of genome altered. Conclusion: WGD occurs more frequently in primary PDA than previously understood, and may confer high levels of genetic instability. Citation Format: Lauren Hummel, Irene Xie, Karen Ng, Amy Zhang, Stephanie Ramotar, Anna Dodd, Grainne O'Kane, Jennifer Knox, Julie Wilson, Steven Gallinger, Faiyaz Notta. The role of whole genome duplication in progression of pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr B036.